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State  of  the  art review  of catheter  designs  for  convection-enhanced  delivery.
Analysis  of the  design  features,  materials  and  methods  of use  which  could  be  applied  to chronic  intermittent  drug  delivery  systems  and  clinical  trials  to
minimise  risk  of trial  failure  and  opportunities  to optimise  intraparenchymal  distributions.
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Background:  Intraparenchymal  convection-enhanced  delivery  (CED)  of  therapeutics  directly  into  the  brain
has long  been  endorsed  as a medium  through  which  meaningful  concentrations  of drug can be adminis-
tered  to patients,  bypassing  the blood  brain  barrier.  The  translation  of  the  technology  to clinic  has  been
hindered  by  poor  distribution  not  previously  observed  in  smaller  pre-clinical  models.  In  part  this  was  due
to the larger  volumes  of  target  structures  found  in humans  but  principally  the poor  outcome  was  linked
to  reﬂux  (backﬂow)  of infusate  proximally  along  the catheter  track.  Over  the  past  10 years,  improvements
have  been  made  to  the technology  in the ﬁeld  which  has  led  to a small  number  of  commercially  available
devices  containing  reﬂux  inhibiting  features.
New method:  While  these  devices  are  currently  suitable  for acute  or short  term  use, several  indica-
tions  would  beneﬁt  from  longer  term  repeated,  intermittent  administration  of therapeutics  (Parkinson’s,
Alzheimer’s,  Amyotrophic  lateral  sclerosis,  Brain  tumours  such  as  Glioblastoma  Multiforme  (GBM)  and
Diffuse intrinsic  Pontine  Glioma  (DIPG),  etc.).
Results: Despite  the  need  for a chronically  accessible  platform  for such  indications,  limited  experience
exists  in this  part  of  the  ﬁeld.
Comparison  with  existing  method(s):  At  the  time  of  writing  no  commercially  available  clinical  platform,
indicated  for chronic,  intermittent  or continuous  delivery  to the  brain  exists.
Conclusions:  Here  we  review  the improvements  that  have been  made  to  CED devices  over  recent  years
and current  state  of  the  art  for chronic  infusion  systems.©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Graphic depiction comparing the distribution associated with convection-
enhanced delivery (CED) and bolus injection (reproduced and modiﬁed from Lam
et  al. (2011)). Note that the region of high concentration has spread laterally a muchReferences  .  .  . . .  . .  . .  .  .  . . . .  . . . .  . . . . . . .  . . .  .  . . .  .  . . .  . . . . .  . . . . . . .  .  . . . . . .  .  . . .
. Introduction
With global population and predicted lifespan increasing, the
revalence of neurological disease is set to rise. At present over 4.6
illion patients have been identiﬁed with Parkinson disease (PD) in
he top 10 populated countries of the west (with an undeﬁned global
opulation) while there are in excess of 20 million patients globally
ho suffer with Alzheimer disease (Dorsey et al., 2007; Kowal et al.,
013). Forecast burden models show predicted volumes of PD cases
oubling within 15–25 years, while Alzheimer disease is predicted
o triple (81.1 million) by 2040 (Lopez, 2011; WHO, 2006). This
ill place a very high demand on healthcare resources all over the
orld.
As has previously been reported, oral and intravascular medi-
ation are ineffective against these types of pathologies given that
1% of systemically administered drugs reach the brain (Stockwell
t al., 2014). A series of tight junctions in the endothelial layer of
he vascular system provides a highly effective ﬁltration system
hat prevents the transport of therapeutic molecules to the tissues
nd ﬂuids of the brain. This ﬁltration system is called the Blood
rain Barrier (BBB) (Bauer et al., 2014).
Bypassing the BBB and delivering therapeutics directly to the
arenchyma, offers the user the ability to introduce therapeutics
ocally, at doses and concentrations that would otherwise have to
e delivered at toxic levels systemically. Bolus injection and the
eliance on natural diffusion from the point of delivery, is not a
alid administration paradigm as the spread of the therapeutic is
imited to a few millimetres from the cannula. Delivery of infusate
ia a pressure driven regime ampliﬁes the distances permeated
y macromolecules and produces a more continuous concentra-
ion distribution (Bobo et al., 1994; Morrison et al., 1994). This
echnique, convection-enhanced delivery (CED), replicates the bulk
ow of ﬂuid through the interstitial spaces observed in natural pro-
esses, such as vasogenic oedema, by increasing the pressure local
o a point source. Therapeutic is driven homogenously into tissues
eyond the infusion boundary that would be achieved by diffu-
ion alone (Fig. 1). Intuitively, smaller molecules were associated
ith larger dispersions than bigger molecules however receptor
inding, charge and other molecular properties also impact on the
istribution of an infusate (Saito et al., 2006).
Despite positive results pre-clinically (Gash et al., 1996) and in
hase I clinician led studies (Gill et al., 2003; Patel et al., 2013; Slevin
t al., 2005) clinical translation of CED has been hampered by high
roﬁle failed studies (Kunwar et al., 2010; Lang et al., 2006). Ret-
ospective investigations have found that overly ambitious study
esign, catheter target accuracy and predictability of distribution
ere major factors failing to achieve successful outcomes (Mueller
t al., 2011; Sampson et al., 2010).
Recent improvements, notably to the delivery platform, has
einvigorated the application of clinical CED with eight active stud-
es registered (ClinicalTrials.gov, 2015). More studies that do not
equire registration may  also be active.
A small number of devices have been commercialised which dis-
lay good acute performance when used with the principles of CED
Brady et al., 2014; Richardson et al., 2011). Progress in this ﬁeld has
herefore focused on acute or short term infusions. These devices
re suited to the delivery of small volume payloads for the deliverylarger distance from the catheter than simply injecting a bolus which is the signature
of  CED.
of viral vectors and stem cells, but little exists in the experience of
chronic CED applications.
Chronic, intermittent delivery could be useful to treat a range of
neurological diseases such as Alzheimer’s, Parkinson’s (Gill et al.,
2003), Gaucher disease (Lonser et al., 2005) among others where
repeated infusions could maintain elevated levels of therapeutic
within a target tissue, where it is quickly cleared or metabolised
(e.g., chemotherapy). While the application of chronic CED may
be useful in the treatment of brain tumours such as Glioblas-
toma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma
(DIPG) tumours, targeting strategies will be key to place long term
catheters in areas of likely recurrence. While direct targeting of a
tumour will deplete its core of dividing cells, the resulting necrotic
core may  act as a sump for further therapeutic delivered, preven-
ting convection into the surrounding tissues. Catheters will need
to be placed around the periphery of a tumour in areas of likely
recurrence.
Broadening the knowledge of this niche has been hindered in
part by the lack of commercially available chronic CED systems to
undertake clinical research. Given the predicted volume of demand
for intraparenchymal delivery options, including chronic adminis-
tration systems, a new appreciation of the ﬁeld must be generated.
Novel, chronic systems will provide clinicians ‘enabling technol-
ogy’ to treat patients and provide the pharmaceutical industry a
new platform to develop therapeutics.
As highlighted in the following review, a large range of catheter
proﬁles have been reported following use in CED infusions. Debin-
ski and Tatter previously highlighted ﬁve categories of catheter
design category (Fig. 2); End Port Cannula (EPC), Stepped Pro-
ﬁles Catheters (SPC), Multi-Port Catheters (MPC), Porous tipped
catheters (PTC) and Balloon Tipped Catheters (BTC) (Debinski and
Tatter, 2009). Designs are not limited to these categories however
and numerous variations and overlaps exist.
O. Lewis et al. / Journal of Neuroscience Methods 259 (2016) 47–56 49
Fig. 2. Device design groups used in CED studies (left to right); End Port Cannula,
Multi-Port Cannula, Porous Tipped Catheters, Balloon Tipped Catheters and Stepped
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droﬁle Catheters—image reproduced and modiﬁed from Debinski and Tatter (2009).
Here we review and consolidate information on catheter design,
xperience and materials which have been published when per-
orming CED infusions in pre-clinical and clinical studies over the
ast 20 years. This review of the state of the art will guide the design
nd optimisation of new chronic intraparenchymal catheters and
heir use.
. Intracranial CED devices
.1. End port cannula (EPC)
Much of the earliest work which categorised the basic knowl-
dge of CED was performed with EPC. While EPC are deﬁned as
aving a singular external proﬁle, no restriction is made to the
aterial, devices can be rigid (e.g., fused silica, PEEK or steel hypo-
ube) or ﬂexible (e.g., polyurethane, silicone).
Bobo et al. (1994) ﬁrst deﬁned the Vd/Vi ratio, a multiplica-
ion ratio used to describe the proportional increase in volume
istributed in the brain (Vd) from the volume infused (Vi). Bobo
bserved that the Vd/Vi ratio was not constant for all infusions.
maller molecules displayed larger distributions (Bobo et al., 1994).
ater studies highlighted that the ratio was also linked to the tis-
ue type, as the interstitial fraction is lower in grey matter than
hite matter (Lieberman et al., 1995). Larger volumes and faster
nfusion rates developed to infuse clinically relevant volumes in
n acceptable timeframe. Increases in ﬂow rates were however
inked to increases in the amount of reﬂux (leakback/backﬂow)
long the catheter track (Chen et al., 1999). Reﬂux is detrimen-
al to CED as the loss of ﬂuid around the point of distribution
rops the local pressure, limiting further distribution. Leakages into
nintended regions can lead to unwanted side effects (Nutt et al.,
003; Tanner et al., 2007). Investigation of infusion parameters
ffecting distribution identiﬁed that increases in cannula diame-
er strongly correlated to increases in the volume and distance of
eﬂux (Chen et al., 1999; Fig. 3) which was also predicted math-
matically (Morrison et al., 1999). Increasing the concentration
f the infusate or delaying the start of an infusion (tissue-to-
atheter sealing time) were discounted experimentally as having
ittle to no effect on reﬂux. However, it was  later shown that
ncreases in tissue trauma (common with larger bore devices) pos-
tively correlated to volume and extent of reﬂux (White et al.,
011). The sealing times described by Chen would not have been
ong enough for healing mechanisms to reduce oedema associ-
ted with local trauma allowing the tissue to seal around the
evice.Fig. 3. Increases in ﬂow rate have been shown empirically to generate increases in
reﬂux along the catheter track—graph reproduced and modiﬁed from Chen et al.
(1999).
2.2. Shunts and peritoneal catheters used for CED (including
multi-port catheters (MPC))
Hydrocephalus shunts, designed for long term implantation in
the brain are routinely used to deliver and aspirate liquids to and
from the ventricles in the brain. They are made from ﬂexible materi-
als such as silicones or polyurethanes. Shunts typically come with
an end port, ﬁsh mouth or multiport design and usually have a
large bore (>1 mm)  to aid the rapid clearance of excess cerebro-
spinal ﬂuid (CSF). Shunts however may  not be optimal for CED as
they lack functional features (i.e., small diameters, reﬂux inhibi-
ting proﬁles, etc.; discussed later) which are critical to effectively
distribute infusates into the interstitial ﬂuids of the brain through
pressure driven means.
Large calibre, ﬂexible end port style ventricular catheters
(2–3 mm outer diameter) that have been implanted in clinical tri-
als to treat glioma have failed to distribute effectively and have
been linked to poor distributions (Kunwar et al., 2010; Tanner
et al., 2007). Cases treating Diffuse Intrinsic Pontine Glioma (DIPG),
assumed spherical distribution but required a low ﬂow rate,
∼1 l/min to delivery (∼6 ml  in 100 h), to minimise the risk of
reﬂux. As no diagnostic tracer was used to conﬁrm the distribu-
tion (as acknowledged by the author) it is not possible to evaluate
the infusion effectively, however, T2 weighted MRI  scans indicated
some elevated signal around the catheter tip (Anderson et al., 2013).
In other phase I clinical trials, multi-port catheters were
implanted into the striatum of patients with promising results
(Slevin et al., 2005). It was suggested that the increased number
of holes may  have aided delivery of therapeutics to the parenchy-
mal  tissues but as no post infusion imaging was performed on the
distribution of these infusions it is impossible to fully qualify this
assertion.
Subsequent investigations of MPC  for CED in gel showed that
they performed poorly (Raghavan et al., 2006; Salvatore et al., 2006)
with preferential ﬂow occurring from the proximal holes.
Investigations of multiport hydrocephalus shunts (Lin et al.,
2003) demonstrated that of the available eight holes along the
device, 80% of the ﬂow escaped from the most proximal three holes
(Fig. 4). This was  proven empirically and then supported through a
Computational model.
Preferential ﬂow seen in hydrocephalus devices might help
explain the patterns of distribution seen in CED studies using these
devices in the opposite ﬂow direction.2.3. Micro porous tipped cannula (PTC)
PTC are similar to MPC  in that they have a number of holes
along their outer wall but PTC have a much larger number of
50 O. Lewis et al. / Journal of Neuroscience Methods 259 (2016) 47–56
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Fig. 5. Microporous tipped cannula (a) illustration of even ﬂow possible over elon-
F
fig. 4. Graphical representation of uneven ﬂow distribution within multiport hy
odiﬁcations to the hole proﬁles and arrangement (white). The distal end is shown
uch smaller holes (≤0.45 m diameter). These holes make up the
orous, ceramic walls in the tips of these devices. During an infu-
ion, each pore experiences a very small volumetric ﬂow which
ill drop the pressure within the core of the device by an equally
mall amount. By maintaining a high internal pressure more dis-
al pores also experience a modest ﬂow which contributes to the
verall distribution along the length of the porous tip (Fig. 5).
When compared to EPC the PTC was shown to increase the dis-
ribution of infusate into the surrounding gel substrate and murine
rain tissue (Oh et al., 2007). A later study found that PTC cannula
roduced a comparable infusion proﬁle to 3 mm step proﬁle can-
ula in vivo (Brady et al., 2013). PTC are being commercialised for
rug delivery by Twin Star Medical.
.4. Balloon tipped catheters (BTC)
While not commonly used in CED trials, a small number of stud-
es have shown that BTC may  have use in treating oncology subjects
ho have undergone resection of their tumour mass. As the penum-
ra of a resection cavity is most at risk of metastasis, it has been
rgued that infusions targeting dividing cells should be admin-
stered preferentially into these areas. Intra-ventricular infusions
ave shown little diffusion of infusate beyond the ependymal layer
f the ventricles (Nutt et al., 2003) while catheters placed too close
o a resection cavity have been linked to losses into these CSF
paces, dramatically stagnating further distribution into surround-
ng tissues (Sampson et al., 2011).
A team at Emory University performed resections in canine sub-
ects with the aim of investigating whether CED could be effectively
sed to distribute infusate into a tumour penumbra by ﬁrst ﬁlling
ig. 6. Infusions into the penumbra of a resection cavity using a 2 channel Gliasite® brach
rom  Olson et al. (2008).gated portions of the device (note blocked tip), (b) radial view of the cannula wall
showing tortuous pathway for infusate through the porous wall—images repro-
duced from Oh et al. (2007).the resection cavity with a balloon (Olson et al., 2008). The study
infused continuously for 4 days at a rate of 83 l/h and stated
that in 2 of 3 cases 97–99% of the brain achieved coverage. The
images of coverage (Fig. 6), however, do not appear to display the
ytherapy catheter, infusing 75% saline/25% Gd-DTPA Magnevist—image reproduced
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omogenous distribution proﬁle associated with CED. The large
overage may  be attributed to the large concentration of the MRI
isible tracer—75% saline/25% Gd-DTPA (Magnevist, Berlex; Olson
t al., 2008) and prolonged period of infusion, with gadolinium
eing carried along with natural parenchymal CSF turnover. Further
ork is required to expand the knowledge for this application.
.5. Stepped proﬁle cannula (SPC) assemblies
Several designs of SPC have been used to perform CED infusions
n clinical and pre-clinical studies. Stepped proﬁles can be produced
hrough the assembly of tubes at the time of implantation or within
 monolithic assembly that is implanted as a single unit, although it
an be argued that the later exhibits much less traumatic delivery
haracteristics for acute delivery.
Monolithic stepped proﬁles were pioneered by a team at the
niversity of California, San Francisco (UCSF) showing that where
nd port cannula alone would have reﬂuxed, the addition of
tepped features would inhibit the progression of backﬂow (Krauze
t al., 2005; Sanftner et al., 2005; Fig. 7).
The distribution of the stepped proﬁle was evaluated ﬁrst in
garose gel containers and later histologically following infusions
n the rat and primate model. Agarose gel is a standard phan-
om material for brain tissue which has been validated against
he porcine brain model (Chen et al., 2004). A monolithic SPC is
eing commercialised by MRI  interventions Inc. which contains a
eramic, fused silica liner and a polymer sheath, though it is cur-
ently approved for intra-ventricular use only.
Research conducted at Cornell University utilised silicon indus-
ry technology to manufacture printed cannula tips containing dual
umen. These can be independently coupled to proximal tubing
way from a delivery site enabling the delivery of a multitude of
nfusates in addition to the integration of sensor technology. This
ould be used during delivery to monitor the local environment or
o actively monitor the infusate itself (ﬂow rate, temperature, air in
ine, etc.; Olbricht et al., 2010). The tip design is being incorporated
nto a stepped proﬁle cannula and commercialised by Alcyone Inc.
hough again, this design is only approved for intra-ventricular use.
Investigations using the dual channel tip were conducted in the
orcine model at varying ﬂow rates with a number of infusates.
hen combined with a stepped proﬁle design comparable distribu-
ions to other SPC were achieved. Infusion rates as high as 20 l/min
ere published for white (internal capsule) and grey (thalamus,
ig. 7. Infusion proﬁles of end port cannula (a, b) and improvement possible through intro
rauze et al. (2005). (e) MRI  interventions – SmartFlow cannula – commercial embodimece Methods 259 (2016) 47–56 51
putamen) matter targets but no investigation of tissue damage was
conducted (Brady et al., 2014). Earlier studies noted tissue damage
at infusion rates in excess of 10 l/min when delivered from a can-
nula with a 102 m diameter bore. The authors speculated that the
tissue damage may  be attributed to the delivery of excessive vol-
ume however subsequent studies have successfully infused larger
volumes (Chittiboina et al., 2014) discounting the theory that vol-
ume  alone is the cause of the observed tissue damage. It is therefore
possible that the tissue damage found by the UCSF team may  be
linked to the ﬂuid velocity at the tip of the catheter. At 10 l/min, a
cannula with a 102 m internal diameter would eject a ﬂuid stream
at 5.1 mm/s. Evaluating the smaller cannula outlet produced by
the micro-fabricated dual channel tips (30 × 53 m2), a comparable
ﬂow rate may  have produced a ﬂuid jet travelling at over 10 times
this rate. It is therefore essential that new cannula and catheter
designs are tested not only for performance with diagnostic imag-
ing but the infusion regimes must be validated at a cellular level to
provide future users a set of safe operational parameters. Further
investigation of this and other designs is therefore warranted.
Prior to the release of commercial alternatives, other groups
treating DIPG clinically have pre-clinically investigated the use of
FS components from Plastics one, a supplier of pre-clinical infusion
systems, before implanting a similar device in humans. A large bore
guide tube (16–18 Gauge) is implanted into the brain stereotacti-
cally and is bonded into a burr hole formed in the cranium, with
the distal tip 15–35 mm short of the target. A primed silica catheter
is then inserted to depth in the guide tube, with the tip located in
the brainstem (Lonser et al., 2002, 2007a,b).
Monolithic SPC usually combine steel or ceramic tubing with
fused silica (FS) liners. This rigid construction is advantageous for
acute infusions as devices can be implanted with a stereotactic
guide system which helps minimise macro-motion during inser-
tion and infusion which is critical to reducing reﬂux (Chen et al.,
2004). Long term implantation of these monolithic assemblies is
not feasible due to the rigidity of the cannula. The relative move-
ment between the brain and the device will promote reﬂux but may
also accelerate natural healing processes. We postulate that as the
brain encases the device in a sheath of glial tissue the permeability
around the cannula will drop which may further increase reﬂux.A modiﬁed hybrid of the monolithic SPC (Fig. 7) made from ﬂex-
ible tubing and a rigid, FS tip was investigated by the same team at
UCSF, Medgenesis Therapeutics and Brainlab AG. This enabled the
device to be implanted in a rigid state (to aid stereotactic delivery),
duction of a reﬂux inhibiting feature (c, d)—images reproduced and modiﬁed from
nt of the stepped proﬁle cannula.
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Fig. 8. Decrease in the intensity of a gadolinium tracer in the brainstem following
the  end of an infusion (A) immediately after completion of the infusion, (B) after
1
c
e
b
d
c
d
t
s
s
(
(
0
u
a
T
a
F
r
ﬂ
e
t
c
r
i
a
i
b
p
f
i
t
i
t
1
t
t
C
b
D
w
a
u h, (C) after 3 h. Note the initial increase in the distribution due to diffusion and
learance processes but the large drop by 3 h post infusion (39% of the Vd at infusion
nd)—images reproduced and modiﬁed from Lonser et al. (2007a).
efore a delivery rod was removed leaving the ﬂexible, indwelling
evice (with rigid tip) in situ. The ﬂexible tubing outside the skull
ould then be routed beneath the skin to a distal exit point. Evi-
ence of acute but not chronic intermittent infusions, in addition
o images of the device were published (Rosenbluth et al., 2011).
Similar, stepped catheter designs were fabricated in Medtronic
ponsored studies. Needle tip catheters were used in a 10 day
tudy in the porcine model, coupled to an implantable pump
Kim et al., 2014) and later a 28 day study in adult primates
Fan et al., 2015). Following a 3 or 7 day infusion (ﬂow rate;
.3 l/min) of a Gd-DTPA solution into the brain, distribution vol-
mes of 1.544 ml  ± 0.420 ml  (Vd/Vi = 1.2) were recorded in the pig
nd 1.936 ± 0.660 ml  (Vd/Vi = 1.68) were recorded in the primate.
he low distribution volumes may  be accounted for by a high clear-
nce rate of Gd-DTPA seen in other studies (Lonser et al., 2007a;
ig. 8). Acute infusions in the primates showed much higher Vd/Vi
atios (5.56 ± 1.6) indicating clearance may  be a major factor in low
ow, continuous infusion.
In order to cover the larger human putamen (3.98 ± 0.15 ml;  Yin
t al., 2009) using this system it may  be necessary to implant mul-
iple catheters with each attached to a pump. Alternatively, higher
overage ratios might be achieved by running the pump at a higher
ate for a short period of time before natural clearance removes the
nfusate from the local area. Continuous infusions were shown to
chieve larger overall infusions. A recent study of prolonged CED
n the rat brainstem (Ho et al., 2015) produced no neurological
ehavioural changes or signs of local toxicity. The relatively short
eriod of the study (10 days) may  not have provided sufﬁcient time
or the onset of local toxicity due to point source accumulation
dentiﬁed in other studies (Barua et al., 2013b).
Flexible guide tube and catheter assemblies, suitable for long
erm implantation, were manufactured speciﬁcally for a phase I
nvestigational study of Glial cell-line Derived Neurotrophic Fac-
or (GDNF) at Frenchay hospital, Bristol, UK (Gill et al., 2003). Sub
 mm diameter catheters and guide tubes were used to minimise
he risk of reﬂux which had been shown to occur in larger diame-
er cannula (Chen et al., 1999). The catheter was manufactured in
arbothaneTM, an aliphatic polyurethane which was later shown to
e critical in achieving low blockage rates (Bienemann et al., 2012).
espite promising clinical outcomes in a small number of cases, it
as not possible to measure infusion performance of this system
s MRI  tracers such as gadolinium (Gd-DTPA) were not routinely
sed.Fig. 9. Assembled catheter design with a reﬂux inhibiting feature: a recessed
step—images reproduced and modiﬁed from Gill et al. (2013).
Successful intermittent infusions performed over 163 days in
the porcine model were demonstrated by the University of Bristol,
utilising a similar system to that described by Gill in 2003. Novel
infusion regimes were used to deliver intermittently which differed
from previous, longer term studies in which ﬂuids were supplied
continuously from an implanted reservoir pump (Bienemann et al.,
2012). The ﬂexible guide tube assembly was further developed with
the incorporation of a third cannula. Instead of a dual step design
the central cannula is cut shorter than the outer tube, producing a
recessed design (Fig. 9).
We have identiﬁed that contrary to the initial description of
CED as a point source event (Bobo et al., 1994), infusions natu-
rally involve a degree of reﬂux which can be incorporated into
the infusion distribution model (Woolley et al., 2013). Immediately
following the start of an infusion, ﬂuid passes into the interstitial
spaces of the surrounding tissue as expected from the standard
model. As the pressure continues to build however the contact
forces between the outer wall of the catheter and the tissue sur-
rounding it will reach a state of equilibrium. At this point ﬂuid will
pass into this space, passing up the outside of the catheter as reﬂux.
As ﬂuid escapes from the tip area the local pressure drops the con-
tact forces high up the catheter track remain high which combined,
stem the ﬂow of ﬂuid.
By embracing and this inevitable reﬂux, we have demonstrated
it is possible to exert a degree of control over it. We have previously
published evidence on the indwelling performance of the recessed
step catheter (Gill et al., 2013) over a month in the porcine model
and subsequently within clinical glioblastoma cases (Barua et al.,
2013a, 2015). While monolithic SPC utilise progressively larger
diameters to inhibit and retard this ﬂow acutely, no chronic infu-
sion data is available therefore their efﬁcacy cannot be stated. A
chronic, pre-clinical infusion system and a similar chronic, clinical
platform are being commercialised by Renishaw PLC.
A novel aspect of the assembled guide tube platform is the abil-
ity to modify the length of the step between the smallest diameter
tube (catheter) and the outer guide tube speciﬁc to each target site.
Together with the recessed step feature, it has been demonstrated
that increasing the protruding step length has the effect of minimis-
ing the volume of reﬂux which travels beyond the ﬂow inhibiting
step feature, achieving a controlled form of reﬂux (Woolley et al.,
2013).
We  have identiﬁed, and will subsequently present data (Lewis,
2015), that it is possible to manipulate infusion morphology
through modiﬁcations to the step length and the infusion regime
of a recessed step catheter. The ability to modify infusion
parameters permits non-surgically invasive optimisation of infu-
sion distributions following implantation and potentially longer
term.
For chronically implanted devices, attributes such as a 90◦ bend
in the tube at the skull surface, and access via a distal port, facilitate
real time monitoring to make informed decisions on the progress
of the infusion.
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A novel accessory described by a team at the University of Wis-
onsin creates a ‘valve tip’ and prevents blockage by occluding
he inner bore of the cannula with a solid rod during insertion.
ollowing insertion the rod is retracted a short distance (∼3 to
 mm)  within the catheter where the inner bore opens slightly
eaving room for ﬂuid to pass around the rod (Sillay et al., 2012).
his design has the additional beneﬁt of reducing the dead volume
ithin implanted systems but will increase the pressure required
o infuse. Comparisons to monolithic stepped cannula designs and
lso microporous tipped cannula showed that the ‘valve tip’ design
roduced comparable infusion proﬁles but no marked improve-
ent in distribution (Brady et al., 2013; Sillay et al., 2012). This
esign would therefore only offer improved robustness and possi-
ly reduced tissue trauma on entry.
. A systems based approach
While this review has focused on catheter design for chronic
ntraparenchymal delivery, previous experience from clinical trials
ndicates that dealing with problem areas in isolation is the root
ause of failures to tackle the clinical translation of CED.
Novel delivery platforms for chronic infusions should there-
ore be founded on the successes pioneered in the acute setting
hile incorporating lessons from previous, failed trials to con-
ider new approaches. While a detailed review of other aspects of
ED is beyond the scope of this review, here we acknowledge the
nter-relationship between the catheter design and other variables.
hronic, repeated delivery is a complex problem with a number of
nterdependent elements that require consideration if optimised,
eliable and repeatable intraparenchymal drug delivery is to be
chieved (Woolley et al., 2013).
This multi factorial approach to successful infusions, depicted
s the pinnacle of the CED pyramid (Fig. 10), relies on expertise and
nowledge across several disciplines. Here it is believed that opti-
al  CED can be attained if based on a solid foundation of effective
tereotaxy, sophisticated surgical planning software, ridged stereo-
actic delivery instruments and appropriate, responsive infusion
umps.
It seems likely that only once a solid platform is achievedan reﬂux resistant chronic drug delivery systems be implanted
ith the required accuracy to ensure that critical catheter fea-
ures are positioned within target structures. The CED pyramid
lso illustrates the need to consider contributing factors that affect
ig. 10. Pyramid of effective drug delivery to the brain—image reproduced and
odiﬁed from Woolley et al. (2013).ce Methods 259 (2016) 47–56 53
particular therapeutics, such as; molecular size, weight, charge,
tissue afﬁnity together with receptor binding, deactivation and
potency levels to material and geometry used in the design of the
implantable device.
Natural variations in the population as well as a changing inter-
nal environment over time due to healing processes present further
complicating factors which demand individual attention and will
require ongoing evaluation to optimise the infusion regimes to
ensure the patient receives treatment where it is required.
4. Discussion
Following years of basic research which characterised the per-
formance issues associated with CED systems, there is now a
growing community which actively use the principles of CED in
pre-clinical and clinical investigations of new and existing drugs.
Despite the immaturity of the knowledge surrounding suc-
cessful implementation of CED systems and the ability to achieve
acceptable coverage of target structures, CED continues to be prac-
ticed within a small number of research centres who  accept the
current limitations, enabling the implantation of infusion devices
based on empirical, historic knowledge and experience of each
device’s prior performance.
A limited number of acute devices have received market
approval, and fewer still have received authorisation for marketi-
sation as CED devices, but no commercially available system is
currently indicated for chronic intraparenchymal delivery.
Drug device combination programmes developing pharmaceut-
icals and improving catheter designs are likely to beneﬁt from
development within a systematic, lab to clinic process where ﬁrst
principles and empirical evidence combine to optimise the delivery.
Translation of device design should start with distribution charac-
terisation in an isotropic, homogenous substrate such as agarose
gel to baseline performance. Distribution properties should then be
conﬁrmed pre-clinically within in vivo models before ﬁnally being
translated to clinical indications.
While only an indicator of infusion morphology, we  have found,
and will subsequently be publishing, that agarose gel infusions
offer baseline infusion morphology data which is speciﬁc to each
device. Reﬂux inhibiting features can be trialled and gain a degree of
supporting empirical evidence before it is trialled in the complex
in vivo environment. Users must appreciate that gel data resents
an excellent starting point which can inform clinical decisions but
this is only a starting point and knowledge of the infusion dis-
tribution properties of the local structures (and more preferably,
prior clinical experience) should be incorporated into the planning
and implementation process. Published evidence of safe, achiev-
able distributions in the in vivo pre-clinical model should also form
the basis of a CED practitioner’s planning arsenal, speciﬁcally whilst
this technique is being adopted and experience gained.
In order to enable optimisation of infusion systems following
implantation, it is beneﬁcial for ﬂexibility to be built in to study
or treatment protocols. It is now obvious that CED infusions must
be visualised following the implantation of chronic infusion sys-
tems to conﬁrm target acquisition and characterise the distribution
achieved. Where poor target structure coverage or other unde-
sirable distributions are observed, clinicians must be given the
knowledge of how best to intervene and optimise the distribution.
It is unacceptable to permit treatments or trials to fail where the
technology exists, and can be easily implemented, to modify the
input infusion regimes and improve outcomes for patients. Such
a controllable infusion system will maximise clinical beneﬁts and
reduce the risk of adverse events while accelerating the develop-
ment of new drugs to clinic. Pre-clinical correlation mapping of a
pharmaceutical agent to imaging tracers should precede clinical
use to ensure representative diagnostic imaging interpretations.
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For chronic infusions, periodic mapping of the distribution,
sing diagnostic imaging tracers, will help characterise ongoing
istribution of therapeutics within target tissues and permit inter-
ention to optimise coverage.
Following the initial description of CED which used simple
annula, development of infusion parameters (ﬂow rate, ramping
egimes, etc.) have preceded device development. Numerous infu-
ion cannula and catheter systems have since been trialled for CED
ith varying degrees of success. Published distribution data indi-
ates that each device performs differently and infusion parameters
hould be developed for each device to optimise distributions. All
ystems will beneﬁt from further investigation and clinical use to
enerate a better understanding of their performance attributes.
 small number of physical attributes appear critical across all
esigns which can be translated to that of a chronically implanted
atheter system.
Larger diameters are linked to increased distance of undesirable
eﬂux along the catheter track. Large diameter tubing is therefore
ndesirable for intraparenchymal delivery. Increases in infusion
ates raise the local pressure around the infusion site and also
ncreases the extent of reﬂux if the pressure surpasses that required
o achieve bulk ﬂow of the interstitial ﬂuid. If reﬂux is observed then
urther distribution is limited as the additional infusate follows the
ath of least resistance around the catheter. Actively dropping an
nfusion rate may  decrease the pressure local to the site of reﬂux
nd halt further progression.
From this review and from our own work, we have found that
 reﬂux inhibiting feature is required to halt backﬂow along the
atheter entry track. Simultaneously this maximises local inter-
titial pressure and achieves bulk ﬂow of the therapeutic into the
issue volume.
For prolonged chronic indications it is essential that the catheter
ystems are made from a ﬂexible material which can move with the
rain during every day activities. All devices must be placed accu-
ately without lateral macro motion as this can increase trauma
nd have a detrimental effect on the distribution.
In addition to physical features, certain practical and transfer-
ble attributes are essential for CED devices to facilitate this novel
reatment regime.
If we accept that the local environment surrounding each
atheter site is unique and each patient speciﬁc, then it is unlikely
hat a standard infusion regime will produce comparable distri-
utions between patients. Catheter speciﬁc optimisation may  be
equired to achieve acceptable coverage of the target structure.
herefore catheter designs need to be ﬂexible so that speciﬁc fea-
ures that inhibit reﬂux can be optimally placed in the intended
arget structure.
Devices must be compatible with imaging modalities such as
RI  (or nuclear imaging in the cases of radio-labelled markers) to
nable real time visualisation of distributions to verify acceptable
overage or intervene and implement a modiﬁed infusion regime
o optimise the distribution. Until a standard model of repeatable
elivery is achieved patient speciﬁc infusion regimes provide a
ractical method of providing patients with optimal coverage of
argeted tissues (Healy and Vogelbaum, 2015). As an emerging ﬁeld,
ED will require specialist clinical infusion pumps and software
hat are capable of running at low infusion rates (0.1–10 l/min).
ump or pump software should have the functionality to house
atient speciﬁc infusion regimes which can be categorised at test
nfusion milestones (e.g., ﬁrst infusion).
There are a range of pre-clinical and clinical options for accessing
ntracranial catheter systems. Active, implantable osmotic pumps
Alzet®) are routinely used to continuously deliver infusate pre-
linically. More recently Primetech Corp. have manufactured a
rogrammable, micro infusion pump containing a 900 l reservoir
hich can be programmed to run intermittently using an on boardce Methods 259 (2016) 47–56
micro-processor (iPrecio®) and a radial peristaltic pump. This micro
pump has a maximum ﬂow rate of 0.5 l/min. While not indicated
for it, the low peak rate would be of limited clinic use to achieve
CED.
Passive subcutaneous access ports (e.g., PinPorts/Soloports-
Instech Solomon, Portacath- Smiths Medical, Porthales- Tricumed
Medizintechnik GmbH, etc.) provide a means of periodically acces-
sing implanted catheter systems injecting into or cutting down to
make the connection immediately prior to an infusion. While sub-
cutaneous ports, osmotic and reservoir pumps can be connected to
intracranial catheters, chronic infusion systems may beneﬁt from
having an externally accessible port to facilitate easy connection
and prolonged attachment during infusions (several hours) with
minimal implanted hardware (Barua et al., 2013b, 2015).
Despite a small number of commercially available reﬂux resis-
tant catheter designs, and some stiff tipped indwelling catheters,
no evidence of their chronic efﬁcacy is available. Further work
is required to develop knowledge of how to implant, optimise
and maintain chronically implanted convection-enhanced delivery
infusion systems.
5. Conclusions
Forecast burden models indicate that the growing and ageing
global population will cause a steep rise in the prevalence of neuro-
oncology and neurodegenerative disease which will place a high
demand on palliative healthcare resources.
Convection-enhanced delivery provides a paradigm for phar-
maceutical and academic institutions to provide not only acute
infusions of gene therapy but also chronic, intermittent infusions of
proteins, neurotrophic factors, chemotherapeutics or other quickly
metabolised molecules.
A small number of dedicated CED devices are starting to enter
the marketplace but are targeted at acute, stereotactic delivery and
indicated for intra-ventricular use. No devices are commercially
available which are indicated for chronic, intermittent CED to the
brain parenchyma.
Targeted chronic catheter and study design should be developed
to enable development of novel treatment regimes which can be
based upon the principles developed within acute delivery systems.
All catheter designs have unique attributes which must be char-
acterised to be used effectively. It should not be assumed that
infusions parameters can be utilised uniformly across all commer-
cially available catheter platforms.
Chronic infusion catheter systems will beneﬁt from small diam-
eters and the inclusion of reﬂux inhibiting features. To remain in the
brain long term, catheters will need to be made from soft materials
but still need to achieve excellent target accuracy which is likely to
require a ‘systems based approach’ which tackles peripheral issues
around the design of the catheter to ensure effective delivery.
Following implantation, and initial characterisation of the dis-
tribution, further periodic test infusions will be required to assess
changes to the distribution pattern which may be caused by heal-
ing mechanisms and natural changes to the internal environment.
In order to do this, device design must facilitate real-time imag-
ing, enable alterations to infusion distribution and be minimally
invasive whilst maximising the patient’s quality of life.
Further work is required to generate understanding of infu-
sion distributions which can be achieved by utilising chronically
implanted CED systems.Disclosures
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